DRAGARWQ vs FISCHER: Stock Comparison
DR. AGARWAL'S EYE HOSP L is the larger company by market capitalisation. DR. AGARWAL'S EYE HOSP L shows a lower P/E, a higher ROE and a higher ROCE, while FISCHER MEDICAL VENTURE L shows a higher dividend yield, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
DRAGARWQ leads 8; FISCHER leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | DRAGARWQ | FISCHER |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Medical Equipment & Supplies |
Price
| Metric | DRAGARWQ | FISCHER |
|---|---|---|
| Live Price | ₹5,077.5 | ₹28.27 |
| Day Change | 0.01% | -4.69% |
| Volume | 1,328 | 4.1 L |
| 52-Week High | ₹6,059.7 | ₹121.7 |
| 52-Week Low | ₹4,600 | ₹29.11 |
| Distance from 52W High | -16.21% | -76.77% |
Valuation
| Metric | DRAGARWQ | FISCHER |
|---|---|---|
| Market Cap | ₹2,455 Cr | ₹1,846 Cr |
| P/E Ratio | 32.2x | 61.33x |
| P/B Ratio | 7.09x | 4.81x |
| EPS | ₹48.38 | ₹0.06 |
| Book Value | ₹716.56 | ₹5.88 |
| Dividend Yield | 0.14% | 0.18% |
Growth
| Metric | DRAGARWQ | FISCHER |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 98.7% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 19.13% | 0% |
| Qtr Profit Growth | 43.97% | 0% |
Profitability & Leverage
| Metric | DRAGARWQ | FISCHER |
|---|---|---|
| ROE | 20.24% | 8.05% |
| ROCE | 18.74% | 7.89% |
| Net Margin | 14.89% | 6.79% |
| Operating Margin | 22.4% | 16.99% |
| Debt to Equity | 0.24x | 0.19x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | DRAGARWQ | FISCHER |
|---|---|---|
| Promoter Holding | 72.67% | 12.31%▲ 0.85 pp |
| FII Holding | 2.24%▲ 0.04 pp | 5.57%▲ 0.09 pp |
| DII Holding | 2.05%▼ 0.07 pp | 1.26%▼ 0.09 pp |
| Public Holding | 23.04%▲ 0.04 pp | 30.09%▼ 0.93 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: DR. AGARWAL'S EYE HOSP L and FISCHER MEDICAL VENTURE L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.